CE

Cellbion Co., Ltd

Develops & manufactures radiopharmaceuticals for cancer diagnosis and therapy.

308430 | KO

Overview

Corporate Details

ISIN(s):
KR7308430008
LEI:
Country:
South Korea
Address:
서울특별시 종로구 대학로 103 서울대학교 암연구소 6층, 종로구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cellbion Co., Ltd. is a clinical-stage biopharmaceutical company specializing in the research, development, and manufacturing of radiopharmaceuticals. The company focuses on advancing Radioligand Therapy (RLT) and antibody-based treatments to address unmet medical needs, particularly in oncology. Its pipeline includes diagnostic imaging agents for PET CT and therapeutic drugs, with a key program targeting Prostate-Specific Membrane Antigen (PSMA) for the diagnosis and therapy of prostate cancer. Cellbion operates a GMP-certified facility for the production of liquid and lyophilized injectable products, supporting both clinical trials and commercial supply.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-12 00:00
Regulatory News Service
투자판단관련주요경영사항(임상시험계획승인신청등결정) (전이성 거세 저항성 전립선암 환자에서 Lutetium(177Lu) …
Korean 12.6 KB
2025-09-09 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB
2025-09-04 00:00
Regulatory News Service
투자판단관련주요경영사항(임상시험결과) (표준요법에 실패한 전이성 거세저항성 전립선암 환자에서 Lu177DGUL의 국내 …
Korean 16.8 KB
2025-08-13 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-06-23 00:00
Regulatory News Service
투자판단관련주요경영사항(임상시험계획승인신청) (전이성 거세 저항성 전립선암 환자에서 Lutetium(177Lu) DGU…
Korean 9.0 KB
2025-05-13 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.1 MB
2025-03-31 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 23.1 KB
2025-03-31 00:00
Share Issue/Capital Change
주식매수선택권부여에관한신고
Korean 15.3 KB
2025-03-31 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 9.9 KB
2025-03-20 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 460.8 KB
2025-03-14 00:00
Audit Report / Information
감사보고서제출
Korean 18.9 KB
2025-03-11 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB
2025-02-28 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 11.8 KB
2025-02-28 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 119.1 KB
2025-01-31 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 11.5 KB

Automate Your Workflow. Get a real-time feed of all Cellbion Co., Ltd filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cellbion Co., Ltd

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cellbion Co., Ltd via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

IN8BIO, INC. Logo
Clinical-stage biopharma developing gamma-delta T cell therapies for solid & hematological tumors.
United States of America
INAB
Develops targeted dermatology & oncology therapies using unique formulation & delivery technologies.
United Kingdom
INC
INCYTE CORP Logo
Develops proprietary therapeutics for serious unmet needs in oncology and inflammation.
United States of America
INCY
Indaptus Therapeutics, Inc. Logo
Develops immunotherapies using engineered bacteria to treat cancer and viral infections.
United States of America
INDP
Indivior PLC Logo
Develops pharmaceuticals for opioid use disorder, addiction, and serious mental illnesses.
United Kingdom
INDV
Infant Bacterial Therapeutics Logo
Develops live bacterial medicines to prevent rare, severe gut diseases in premature infants.
Sweden
IBT
InflaRx N.V. Logo
Develops complement system inhibitors for severe inflammatory diseases and immuno-dermatology.
United States of America
IFRX
Inhibikase Therapeutics, Inc. Logo
Develops kinase inhibitors to treat neurodegenerative diseases like Parkinson's.
United States of America
IKT
Inhibrx Biosciences, Inc. Logo
Clinical-stage biopharma developing novel biologic therapies for life-threatening cancers.
United States of America
INBX
InMed Pharmaceuticals Inc. Logo
Develops cannabinoid drugs for unmet medical needs and supplies rare cannabinoids for B2B wellness.
United States of America
INM

Talk to a Data Expert

Have a question? We'll get back to you promptly.